CD19 and acute lymphoblastic leukemia: Immunophenotypic analysis of primary blast cells from patients with KMT2Ar ALL, in agreement with our previous study,14 showed coexpression of CD19 and CD133, with a 67% median level of CD133 coexpression (range 0%-100%; supplemental Figure 1A-B).